Bank of New York Mellon
IKT icon

Bank of New York Mellon’s Inhibikase Therapeutics IKT Stock Holding History

Bank of New York Mellon’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$615K Buy
303,126
+89,918
+42% +$161K ﹤0.01% 3647
2026
Q1 		$358K Buy
213,208
+75,723
+55% +$134K ﹤0.01% 3764
2025
Q4 		$282K Sell
137,485
-1,182
-0.9% -$1.88K ﹤0.01% 3891
2025
Q3 		$225K Buy
138,667
+6,194
+5% +$10.7K ﹤0.01% 3971
2025
Q2 		$258K Buy
+132,473
New +$259K ﹤0.01% 3874
2023
Q2 		– Sell
-6,501
Closed -$25.7K – 4425
2023
Q1 		$25.7K Hold
6,501
– – ﹤0.01% 4282
2022
Q4 		$19.5K Sell
6,501
-51
-0.8% -$202 ﹤0.01% 4361
2022
Q3 		$36K Hold
6,552
– – ﹤0.01% 4373
2022
Q2 		$29K Sell
6,552
-45
-0.7% -$265 ﹤0.01% 4447
2022
Q1 		$59K Hold
6,597
– – ﹤0.01% 4498
2021
Q4 		$58K Hold
6,597
– – ﹤0.01% 4477
2021
Q3 		$75K Buy
+6,597
New +$89.2K ﹤0.01% 4382

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Bank of New York Mellon's IKT Position: Q2 2026 in Review

Bank of New York Mellon increased its Inhibikase Therapeutics (IKT) stake by 42% in Q2 2026, buying an estimated $161K and bringing the position to 303,126 shares worth $615K. The position accounts for ﹤0.01% of the portfolio, ranked #3647.

Bank of New York Mellon first reported a position in IKT in Q3 2021 and has held it in 12 quarters since. 64 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Bank of New York Mellon held 303,126 shares of Inhibikase Therapeutics worth $615K as of Q2 2026.
  • Bank of New York Mellon bought 89,918 Inhibikase Therapeutics shares in Q2 2026, an estimated $161K.
  • Inhibikase Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3647 holding.
  • Bank of New York Mellon first reported a position in Inhibikase Therapeutics in Q3 2021 and has held it in 12 quarters since.
  • 64 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.